Antirheumatic Therapy: Actions and Outcomes

Front Cover
Richard O. Day, Daniel E. Furst, Piet L.C.M. van Riel, Barry Bresnihan
Springer Science & Business Media, May 30, 2010 - Medical - 343 pages
0 Reviews
Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

Medicinal chemistry of the disease modifying antirheumatic drugs
1
Targeting DMARD therapy
25
Pharmacoeconomic properties of diseasemodifying antirheumatic drugs
49
Future molecular targets
69
Hydroxychloroquine
81
Sulfasalazine
93
Parenteral gold
133
Azathioprine
163
Cyclosporin
221
Tetracyclines
237
Systemic glucocorticoids in rheumatoid arthritis
247
TNFα inhibitors
265
Anakinra in rheumatoid arthritis
279
Combination therapy
293
Hematopoietic stem cell transplantation for the treatment ofsevere autoimmune diseases
319
Index
337

Methotrexate
175
Leflunomide
199
The PIRSeriesProgress in Inflammation Research
344
Copyright

Other editions - View all

Common terms and phrases

About the author (2010)

DANIEL E. FURST, M.D., is the first Carl M. Pearson Professor of Rheumatology at UCLA.

Bibliographic information